Quality of Life after Radioembolization for Hepatocellular Carcinoma Using a Digital Patient-Reported Outcome Tool

J Vasc Interv Radiol. 2020 Feb;31(2):311-314.e1. doi: 10.1016/j.jvir.2019.06.018. Epub 2019 Nov 13.

Abstract

Health-related quality of life (HRQoL) measurements are important for patient care, and emerging bundles in value-based care are placing an increasing emphasis on tying reimbursement to patient surveys. A multicenter pilot study was carried out to assess the efficacy of an automated digital patient engagement (DPE) platform for collecting HRQoL measurements at baseline and at 2- to 4-week intervals through 90 days after transarterial radioembolization (TARE) with yttrium-90 (90Y) treatments for hepatocellular carcinoma (HCC). The results revealed a survey completion of 78.4% and demonstrated only 4 of 35 individual symptom instances across all time points of transient worsening relative to baseline. Most importantly, the DPE platform provided an effective means for deploying and collecting patient-reported outcome measures.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / radiotherapy*
  • Embolization, Therapeutic* / adverse effects
  • Humans
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / radiotherapy*
  • Patient Reported Outcome Measures*
  • Pilot Projects
  • Predictive Value of Tests
  • Quality of Life*
  • Radiopharmaceuticals / administration & dosage*
  • Radiopharmaceuticals / adverse effects
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Yttrium Radioisotopes / administration & dosage*
  • Yttrium Radioisotopes / adverse effects

Substances

  • Radiopharmaceuticals
  • Yttrium Radioisotopes